【摘要】 目的：评价司氟沙星注射剂治疗细菌性感染的疗效和安全性。方法：采用随机对照开放试验，在三所医院临床观察本品治疗各种感染１００例，其中６０例与氧氟沙星作随机对照；司氟沙星２００ｍｇ—３００ｍｇ；氧氟沙星２００ｍｇ，ｂｉｄ。结果：司氟沙星临床有效率、细菌清除率、细菌敏感率和不良反应发生率分别为８３．３％、９１．１％、９３．９％、１２％，氧氟沙星为８１．７％、９０％、９１．４％、１０％，两组疗效和安全性经统计学处理无显著性差异（Ｐ＞０．０５）。司氟沙星的主要副反应为胃肠道反应和皮疹，无光过敏反应发生。结论：司氟沙星抗菌谱广，抗菌活性强，每天用 ２００ｍｇ治疗敏感菌所致的中至重度感染有较好的临床疗效。更多还原

【Abstract】 Objective: To evaluate the clinical efficacy and safety of intravenous sparfloxacin lactate (SPLX) administration in the treatment of bacterial infections. Methods: A randomized open trial was conducted in 3 multicenter controlled trials. 160 patients were admitted into the study, including 60 cases in the control group (ofloxacin,OFLX).The dosage of SPLX was 200mg qd and that of OFLX was 200mg bid. Results-. In the SPLX group,88.3% of patients were clinically cured or improved compared with 81.7% of the patients in the OFLX group (P>0.05).The eradication rates of pathogens were 91.1% and 90% ,respectively (P>0.05). Bacterial eradication rates were similar in both treatment groups. Drug -related adverse events were reported in 12% of patients receiving SPLX and in 10% of patients administered of OFLX. Gastrointestinal and rash adverse events were the most common ones reported in each treatment group. There is no photosensitivity reaction in both groups. The results of in vitro activity of SPLX showed good activity against many Gram - negative organ- isms and were similar to those of OFLX. The activity against Gram- positive organisms was higher than that of OFLX. Conclusion : Intravenous treatment with 200mg SPLX qd is as effective as the treatment with 200mg OFLX bid in patients with acute and serious infectious diseases caused by sensitive pathogens.更多还原